Edition:
United States

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

6.97USD
4:00pm EDT
Change (% chg)

$0.02 (+0.29%)
Prev Close
$6.95
Open
$7.00
Day's High
$7.14
Day's Low
$6.88
Volume
425,993
Avg. Vol
712,503
52-wk High
$7.14
52-wk Low
$1.96

Latest Key Developments (Source: Significant Developments)

Seattle Genetics in licensing deal with Immunomedics
Friday, 10 Feb 2017 07:24am EST 

Seattle Genetics Inc : Seattle Genetics announces global license agreement with immunomedics for sacituzumab govitecan (immu-132), a promising late-stage adc for solid tumors . Seattle Genetics Inc - planned bla for triple negative breast cancer indication; other solid tumors being explored in clinic . Seattle Genetics Inc - seattle genetics to lead development, manufacturing and commercialization of sacituzumab govitecan globally . Seattle Genetics inc says seattle genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics -upon closing of transactions contemplated by development, license agreement, immunomedics would receive an upfront payment of $250 million . Seattle Genetics Inc - granted right to purchase an additional 8,655,804 shares of common stock at a price of $4.90 per share . Seattle Genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics - would pay development, regulatory,sales-dependent milestone payments across multiple indications of up to total maximum of about $1.7 billion . Seattle Genetics Inc - 2017 guidance provided on february 9, does not take into account impact of transactions with immunomedics.  Full Article

Immunomedics announces Q2 fiscal 2017 results and clinical program developments
Thursday, 9 Feb 2017 04:00pm EST 

Immunomedics Inc : Immunomedics announces second quarter fiscal 2017 results and clinical program developments . Immunomedics Inc says total costs and expenses for quarter ended December 31, 2016 were $15.7 million, compared to $16.4 million for same quarter in fiscal 2016 . Q2 loss per share $0.23 .Q2 revenue fell 43 percent to $400,000.  Full Article

Immunomedics announces novel immuno-oncology program targeting Trop-2-expressing cancers
Monday, 12 Dec 2016 07:00am EST 

Immunomedics Inc : Immunomedics announces novel immuno-oncology program targeting Trop-2-expressing cancers . Completing enrollment of 100 TNBC patients into ongoing phase 2 clinical trial of IMMU-132 by year-end 2016 . Immunomedics - submitting a biological license application to FDA for accelerated approval for IMMU-132 for patients with metastatic TNBC in mid-2017 .Immunomedics - presenting interim results of phase 2 clinical trials for patients with urothelial cancer at a symposium on genitourinary cancers to be held in early 2017.  Full Article

Immunomedics reports Q4 loss per share $0.17
Wednesday, 17 Aug 2016 04:00pm EDT 

Immunomedics Inc : Immunomedics announces fiscal 2016 results and clinical program developments . Q4 revenue fell 63 percent to $900,000 . Q4 loss per share $0.17 . Total revenues for Q4 ended June 30, 2016, were $0.9 million, compared to $2.4 million for same quarter last year . Says "We plan to spend approximately $42 million to $44 million during fiscal 2017" .Immunomedics inc says believe current funds are sufficient to continue operations and budgeted research and development programs.  Full Article

Immunomedics says appoints Garone as new CFO
Tuesday, 21 Jun 2016 08:00am EDT 

Immunomedics Inc : Immunomedics appoints Michael R. Garone as new chief financial officer . Immunomedics Inc says Garone replaces Peter P. Pfreundschuh . Immunomedics Inc says Peter P. Pfreundschuh will serve as a consultant to company for next few months to ensure a smooth transition .Immunomedics appoints Michael R. Garone as new chief financial officer.  Full Article

Immunomedics, Inc reports continuing positive results with Sacituzumab Govitecan
Thursday, 10 Dec 2015 08:30am EST 

Immunomedics, Inc:Reports continuing positive results with sacituzumab govitecan in heavily pre-treated metastatic triple-negative breast cancer patients.Sacituzumab govitecan has an acceptable interim safety profile in the 60 mtnbc patients reported at the symposium.  Full Article

Immunomedics Inc reports interim phase 2 results with sacituzumab govitecan in lung cancers
Tuesday, 8 Sep 2015 07:00am EDT 

Immunomedics Inc:Says sacituzumab govitecan continues to produce durable responses in patients with metastatic lung cancer.The antibody-drug conjugate also continues to demonstrate a highly tolerable and easily managed toxicity profile, despite repeated dosing.  Full Article

Immunomedics Inc announces orphan drug designation for Veltuzumab for treatment of immune thrombocytopenia
Tuesday, 4 Aug 2015 08:30am EDT 

Immunomedics Inc:Says Office of Orphan Products Development of U.S. Food and Drug Administration (FDA) has granted orphan status for use of veltuzumab, company's humanized anti-CD20 antibody, for treatment of immune thrombocytopenia (ITP).In a Phase 1 study,(1)low-dose veltuzumab, as single agent, produced an objective response rate of 55 pct in 38 response-assessable patients with relapsed ITP, including 11 patients (29 pct) who reported complete response.Furthermore, 10 responders achieved durable responses for more than 1 year, including 3 patients in remission for up to 4.3 years after veltuzumab treatment.Says Phase 2 expansion trial has completed patient accrual and patients are being followed for up to 5 years.  Full Article

Immunomedics says labetuzumab govitecan is active in relapsed metastatic colorectal cancer
Tuesday, 2 Jun 2015 10:24am EDT 

Immunomedics:Reports labetuzumab govitecan is active in relapsed metastatic colorectal cancer.Says labetuzumab govitecan was well tolerated by patients.  Full Article

Immunomedics announces durable responses in metastatic lung cancer patients treated with sacituzumab govitecan
Tuesday, 2 Jun 2015 10:12am EDT 

Immunomedics:Says sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), demonstrated in a mid-stage clinical study promising anti-tumor activity in patients with metastatic lung cancer.Says these patients had either failed to respond to their last cancer therapies or their cancer had returned or progressed.  Full Article

More From Around the Web

BRIEF-Seattle Genetics says court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics

* Seattle Genetics- On March 9,court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics